Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12029226 | 0.92 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1ALOX15TSHRMAPT | |
| SCHEMBL12029122 | 0.91 | BRAF (0.51) | SMN1; SMN2BRAFALDH1A1ALOX15TSHR | |
| SCHEMBL12029187 | 0.89 | L3MBTL1 (0.52) | SMN1; SMN2ALDH1A1ALOX15TSHRMAPT | |
| SCHEMBL12029225 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1ALOX15TSHRMAPT | |
| SCHEMBL12029232 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1ALOX15TSHRMAPT | |
| SCHEMBL12029234 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1ALOX15TSHRMAPT | |
| SCHEMBL12029120 | 0.84 | ALDH1A1 (0.47) | SMN1; SMN2BRAFALDH1A1ALOX15TSHR | |
| SCHEMBL12029249 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1ALOX15TSHRMAPT | |
| SCHEMBL12029282 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2BRAFALDH1A1ALOX15TSHR | |
| SCHEMBL12029227 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1ALOX15TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326986-B2 | Quinazolinone, quinolone and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2016-05-03 | — | — | US | disclosed |
| US-9326986-B2 | Quinazolinone, quinolone and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2016-05-03 | — | — | US | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2010037129-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | SMN1; SMN2 3331/4885BRAF 3247/4885ALDH1A1 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.